Martin Wanyoike Njoroge

Search results

• 2023

  Burosumab for treating X-linked hypophosphataemia in adults: External Assessment Group Report for the National Institute for Health and Care Excellence

  Llewellyn, A., Zhou, A., Phung, H., Njoroge, M. W., Harden, M., Walker, S. M., Simmonds, M. C. & Rothery, C., Nov 2023, National Institute for Health and Care Excellence.

  Research output: Book/Report › Commissioned report

• Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

  Walton, M. J., Corbett, M. S., Dwan, K., Njoroge, M. W., Fulbright, H. A., Uphoff, N., Hodgson, R. & Dias, S., 11 May 2023, National Institute for Health and Care Excellence.

  Research output: Book/Report › Commissioned report

• Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

  Walton, M. J., Corbett, M. S., Njoroge, M. W., Beresford, L., Harden, M., Hodgson, R. & Dias, S., 9 Feb 2023

  Research output: Book/Report › Commissioned report

• Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer

  Rodgers, M., Walton, M. J., Anwer, S., Corbett, M. S., Njoroge, M. W., Fulbright, H. A., Naik, R., Powell, M., Eastwood, A. J. & Hodgson, R., 29 Mar 2023, National Institute for Health and Care Excellence.

  Research output: Book/Report › Commissioned report